Chemomab Therapeutics (CMMB) Tops Q4 EPS by 5c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• SanDisk upgraded at JPMorgan after investor day; shares climb